Voyager Therapeutics (VYGR) Fundamental Analysis: Revenue, Earnings & Valuation

3.44 / 10

Netural

Fundamental score is 3.44/10, indicating poor health. Valuation ratios like PB‑ROE and cash‑to‑market are modest, but asset‑to‑market and YoY revenue decline (-49%) drag performance. Overall rating remains neutral with constrained growth prospects.

Analysis Checks(8/10)

Revenue-MV

Value-0.94

Score2/3

Weight18.77%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-49.53

Score2/3

Weight-1.85%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.30%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.49%

1M Return1.69%

PB-ROE

Value-0.21

Score2/3

Weight14.48%

1M Return6.97%

Income tax / Total profit (%)

Value-0.12

Score2/3

Weight2.05%

1M Return1.04%

Fixed assets turnover ratio

Value0.90

Score1/3

Weight-2.13%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.85%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight27.45%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight13.59%

1M Return5.94%

Is VYGR fundamentally strong?

VYGR scores 3.44/10 on fundamentals and holds a Fair valuation at present. Backed by its -48.29% ROE, -296.53% net margin, -1.93 P/E ratio, 1.18 P/B ratio, and -80.53% earnings growth, these metrics solidify its Netural investment rating.